TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. has renewed its distribution collaboration with Sinopharm, extending the agreement until December 2028. This renewal, subject to Hong Kong Listing Rules, positions Sinopharm as a key distributor of Henlius’s products, impacting the company’s market reach and operational strategy. The agreement’s renewal underscores the strategic importance of Sinopharm in Henlius’s distribution network and involves compliance with connected transaction regulations, necessitating shareholder approval and independent financial advice.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and distribution of biopharmaceutical products. The company is involved in producing and distributing a range of therapeutic products, with a market focus on leveraging partnerships for distribution, such as its collaboration with Sinopharm.
Average Trading Volume: 1,465,995
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.77B
See more data about 2696 stock on TipRanks’ Stock Analysis page.